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provided it is propeBackground: Children with perinatally acquired HIV (paHIV) remain at an increased
risk of pneumococcal infection despite highly active antiretroviral therapy (HAART).
Beyond infancy, responses to pneumococcal conjugate vaccine (PCV) remain under-
investigated. There are currently no published data on serological response to 13-valent
PCV (PCV13) in the HIV-infected populations.
Methods: We measured pneumococcal serotype-specific IgG in 48 paHIV-infected
child patients (CP), 27 young adult healthy controls (AHC) and 30 child healthy controls
(CHC). Opsonophagocytic assay (OPA) titres for three PCV13-exclusive serotypes were
measured in a subset of children. Serotype-specific IgG was repeated 1 and 6 months
following PCV13 vaccination of CP and AHC groups. OPA titres for four serotypes were
measured at the 1-month time-point.
Results: Themajority of CP, CHC and AHChad serotype-specific IgG above 0.35mg/ml
at baseline, although OPA activity was undetectable for two of the three serotypes
studied. Baseline IgG concentrations were significantly lower in CP than AHC for a
proportion of serotypes and were strongly predictive of responses to vaccine. After
adjusting for baseline, postvaccination IgG concentrations were comparable, although
responses to some serotypes were impaired for CP. OPA correlated well with IgG after
vaccination. Detectable HIV viral load was associated with significantly lower IgG
concentration and OPA titre.
Conclusion: Children with paHIV mount a robust serological response to PCV13 for
most but not all vaccine serotypes. Viral load suppression with HAART and higher
baseline IgG concentration are associated with higher postvaccination antibody levels.
This has implications for HAART treatment and vaccination practices.
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Children with perinatally acquired HIV (paHIV)
receiving HAART continue to have an increased risk
of invasive pneumococcal disease (IPD) [1]. Pneumo-
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rly cited. The work cannot be changed in any way owhen administered to HIV-infected infants [2,3] and
adults [4], and should therefore be efficacious in older
children and adolescents with paHIV. However, there are
no published data to date on 13-valent PCV (PCV13) in
any HIV-infected age group and few studies of licensed
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2034 AIDS 2014, Vol 28 No 14Studies of lower-valency PCVs (ranging from 4 to 9
serotypes) in HIV-infected individuals including infants,
older children and adults have generally shown that
immunogenicity is impaired in comparison to healthy
controls (reviewed in [13]). The response to pneumo-
coccal vaccination is likely to be different in older
children with paHIV compared to HIV-infected infants
or adults. In infants with paHIV, pneumococcal conjugate
vaccine will mainly induce a primary response, on the
background of an immature immune system already
burdened with high viral loads, immune activation and
CD4þ T-cell depletion [14]. In contrast, adults with
horizontally acquired HIV have already encountered
pneumococci and established a degree of immunity to
many of the pathogenic serotypes by the time of
acquisition of HIV [15]. Pneumococcal vaccination
response in this context will be determined in part by the
specific impact of HIV on the fully developed and
pneumococcal antigen-experienced immune system.
Although an older child with paHIV has survived
infancy, their immune system has developed (or is still
developing) under the influence of HIV, with or without
the benefit of HAART. They are likely to have some
degree of pneumococcal immunity through natural
exposure, but this will have been modified by alterations
of both the innate and acquired immune system related to
HIV infection. Abnormalities of immune phenotype
found to be characteristic of this patient group are likely
to impact on the responses to PCV.
Debate as to whether PCV13 should be recommended
for older children in risk groups such as paHIV is ongoing
[16–19]. There is little evidence to guide practice with
respect to timing of immunization relative to HAART
and dosing schedules in older children. Immunogenicity
data make an essential contribution to evidence-based
vaccination guidelines and policy for at-risk groups. In
order to provide immunogenicity data while investigating
factors affecting vaccine response, we studied both
quantitative and qualitative responses to PCV13 and
analysed them according to treatment history, viral load
and other clinical parameters in a cohort of children and
adolescents with paHIV.Methods
Study population and design
The study took place in the HIV Family Clinic at
Imperial College Healthcare National Health Service
(NHS) Trust, St Mary’s Hospital, London, UK, between
August 2009 and October 2012. Children with paHIV
and healthy HIV-uninfected children aged between
2 months and 18 years, and young HIV-uninfected
adults aged between 18 and 30 years were recruited from
the HIV Family Clinic, routine preop assessment clinics/
general practitioner (GP) phlebotomy clinics and throughpyright © Lippincott Williams & Wilkins. Unauthoadvertisement in Imperial College London, respectively.
Exclusion criteria included other causes of immunosup-
pression, previous reaction to PCV or its components,
current febrile illness and pregnancy. Ethical approval was
obtained from theRiverside Research Ethics Committee,
Charing Cross Hospital, London (Reference: 09/
H0706/23). Parents of children included in the study
and adult controls provided written informed consent.
For child cohorts, background demographic and clinical
information were obtained from clinical notes and GP,
hospital pathology and Personal Child Health records. For
adult controls information was obtained from interview
and/or GP records.
Perinatally acquired HIV-infected child patients had
blood sampled at baseline for lymphocyte subsets (LSS),
plasma HIV-RNAviral load and serological studies. They
then received one dose of PCV13 [2.2mg pneumococcal
polysaccharides 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F,
23F and 4.4mg 6B, conjugated to CRM197 carrier
protein, adsorbed on aluminium phosphate (0.125mg
aluminium)] (Pfizer, UK; batch number: E27415),
administered as an intramuscular injection into the
anterolateral thigh for infants and the deltoid muscle for
older children and adults. Vaccinees and their families
were asked to contact the research team should they suffer
adverse events. History of adverse events was sought at
each contact. Blood samples were obtained at 1 month
and again at 6–9 months after immunization. Child
healthy controls (CHC) had blood sampled once only for
LSS and serological studies. For young adult healthy
controls (AHC), blood sampling and vaccination was as
for the CP cohort. For ethical and logistic reasons, only
CP and AHC were vaccinated with PCV13. The CHC
group was included to enable an age-related assessment of
baseline immunity and in order to validate the suitability
of AHC as a control group.
Laboratory methods
HIV viral load was measured using branched-chain DNA
assay (Siemens Healthcare, Sudbury, UK) with a lower
limit of detection of 50 copies/ml, and quantitation of
LSS was undertaken by staining whole blood (EDTA)
with monoclonal antibodies [CD45-FITC, CD4-RD1,
CD8-ECD, CD3-PC5, CD56-RD1, CD19-ECD,
CD16-PE (Beckman Coulter Inc., High Wycombe,
UK)] and evaluated using FC500 flow cytometer
(Beckman Coulter Inc.) via NHS laboratory services.
Serological assays were performed in the WHO reference
laboratory for pneumococcal serology at the Institute of
Child Health, London, UK. Pneumococcal capsular
polysaccharide-specific IgG for all PCV13 strains was
measured by ELISA after absorption with cell wall and
22F polysaccharide. Opsonophagocytic assay (OPA) was
performed according to methods of Romero-Steiner
using the promyelocytic HL60 cell line. Detailed
protocols for both methods are available at http://
www.vaccine.uab.edu/.rized reproduction of this article is prohibited.
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For baseline characteristics and LSS, chi-square and
Fisher’s exact tests were used to compare proportions.
Mann–Whitney U test was used to compare age and
baseline LSS between the child and adult groups. To
compare LSS between child groups, data were log-
transformed and compared using linear regression analysis
to allow adjustment for age and to assess age group
interactions. For serological data, chi-square and Fisher’s
exact tests were used to compare baseline proportions
above a cut-off between groups. A cut-off of 0.35mg/ml
was chosen as this is an accepted correlate of protection in
PCV immunogenicity studies in infants [20]. A more
conservative cut-off of 1mg/ml, potentially more relevant
to long-term protection and allowing comparison with
other published data in children with paHIV [11], was
included in the analysis. One-way analysis of variance
(ANOVA) with Bonferroni correction was used to
compare log-transformed antibody concentrations and
OPA titres at baseline between groups. Chi-square was
used to compare proportions above a cut-off between
groups at each time-point after immunization. McNe-
mar’s test was used to detect changes in proportion from
baseline within groups. Repeated-measures ANOVA and
analysis of covariance were used to compare log-
transformed antibody concentrations between and within
group. Post-hoc analyses for simple effects were then
performed as appropriate. Linear regression was used to
assess for associations between clinical parameters and
log-transformed serology at baseline and 1 month after
immunization. Factors assessed included: HIV viral load
above 50 copies/ml (yes/no), HAART commenced in
the first year of life (yes/no), HAART commenced in theCopyright © Lippincott Williams & Wilkins. Unaut
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Fig. 1. Overview of study recruitment. One CP withdrew consent
study entry according to inclusion criteria, one AHC was exclude
AHC, adult healthy control; CHC, child healthy control; CP, child p
OPA, opsonophagocytic assay.first 2 years of life (yes/no), received PCV7 (yes/no),
received pneumococcal polysaccharide vaccine (PPV)
(yes/no), proportion of life with undetectable viral load
and nadir CD4þ percentage. A value of P less than 0.05
was considered statistically significant while acknowl-
edging that a lower cut-off might be considered more
appropriate in the context of multiple comparisons. Data
were analysed using Stata IC version 12.1 for Mac
(StataCorp, College Station, Texas, USA) and Prism 5 for
Mac OS X (GraphPad, La Jolla, California, USA).Results
Recruitment and baseline characteristics
An overview of study numbers and recruitment are
shown in Fig. 1. Baseline characteristics are summarized
in Table 1. In line with the study design and target
populations, there were significant expected differences
in ethnicity and country of birth (48% of CPwere born in
Africa). For those CP who had ever started HAART,
median age at HAART initiation was 41 months [inter-
quartile range (IQR) 11–91 months]. Sixty-five percent
commenced HAART before 5 years of age. Median BMI
centile for CP was 55% (IQR 25–91%). Sixty-three
percent had a BMI centile greater than 50%. Twenty-
three percent of CP had ever had an opportunistic
infection. No AHC had received PCV or PPV, and no
study participant had ever received PCV13. Prior to study
entry, 20.1 and 4.2% of CP had received one or two doses
of PPV, respectively (median time since last dose of PPV
46 months). Two and three doses of PCV7 were receivedhorized reproduction of this article is prohibited.
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prior to blood sampling, one CP was found to be ineligible for
d from 1-month serology analysis due to insufficient sample.
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Table 1. Baseline characteristics for all study participants.
CHC (n¼30) AHC (n¼26) CP (n¼48)
Sex
Female 14 (46.7) 15 (57.7) 21 (43.8)
Male 16 (53.3) 11 (42.3) 27 (56.3)
Ethnicity
White 4 (13.3) 19 (73.1) 2 (4.2)
Mixed 0 (0) 2 (7.7) 3 (6.3)
Asian 0 (0) 3 (11.5) 2 (4.17)
Black Caribbean 4 (13.3) 0 (0) 2 (4.17)
Black African 13 (43.3)a 0 (0) 38 (79.2)b
Other 9 (30) 2 (7.7) 1 (2.1)
Born in UK 29 (96.7)a 20 (74.1) 24 (50)b
Age/months 107.5 (19–195) 330c (245–359) 154d (12–209)
Previous PCV7 9 (30.0) 0 (0) 7 (14.6)
Previous PPV 0 (0) 0 (0) 12 (25.0)
Nadir CD4% – – – – 13 (0–48)
Prop – – – – 0.49 (0–0.98)
VL <50 copies/ml – – – – 37 (77.1)
Antiretroviral treated 1st year – – – – 7 (14.9)
Antiretroviral treated 1st 2 years – – – – 12 (25.3)
LSS
Lymph cells/ml 2139 (1666–3414) 1807.5e (1377–2115) 2349.5f,g (1764–3308.5)
CD3 cells/ml 1575.5 (1166–2486) 1389d,e (1094–1706) 1854.5h (1390.5–2518)
CD3% 71.6 (66.6–78.3) 75.3 (70.1–79.1) 75.45 (68.9–79.6)
CD4þ cells/ml 833.5 (647–1391) 794 (694–1061) 855h (525.5–1118)
CD4% 43.1 (36.7–46.5) 44.6e (39.8–50.6) 34.55h (27.2–40.8)
CD8þ cells/ml 529.5 (356–907) 497e (383–557) 913.5f,g (659–1074.5)
CD8% 23.8 (21.6–27.2) 26.3e (22.2–28.9) 32.95h (28.9–44.5)
CD19 cells/ml 446.5 (272–679) 257d,e (153–326) 403f (266–570.5)
CD19% 18.2 (14.5–24.2) 12d,e (8.9–16.8) 17.3f (12.96–21.4)
CD56 cells/ml 134.5 (82–205) 172.5e (96–188) 119h (72–184.5)
CD56% 5.4 (2.9–8.2) 9.4d,e (6.5–12.1) 4.35 (2.8–5.6)
Sex, ethnicity, UK origin, HIV viral load status, treated in the first year of life, treated in the first 2 years of life, previous PCV7 and previous PPV are
presented as number and percentage. Age, nadir CD4% and proportion of life undetectable are presented as median and range. Lymphocyte
subsets are presented as median and inter-quartile range. Chi-square and Fisher’s exact tests were used to compare proportions. Mann–Whitney
U test was used to compare age and baseline LSS between the child and adult groups. To compare LSS between child groups, data were log-
transformed and compared using linear regression analysis to allow adjustment for age and to assess age group interactions. AHC, adult healthy
control; CHC, child healthy control; CP, child patient; LSS, lymphocyte subsets; PCV7, 7-valent pneumococcal conjugate vaccine; PPV,
pneumococcal polysaccharide vaccine; Prop, proportion of life spent with undetectable viral load; VL, HIV viral load.
aProportion significantly different: CHC vs. AHC (P<0.05).
bProportion significantly different: CP vs. CHC (P<0.005).
cMedian significantly different from CP and CHC (P<0.001).
dMedian significantly different from CHC (P<0.05).
eMedian significantly different from CP (P<0.05).
fSignificant independent age effect when comparing CHC vs. CP (P<0.05).
gSignificant independent group effect when comparing CHC vs. CP (P<0.05).
hSignificant age group interaction when comparing CHC vs. CP (P<0.05).by 3.6 and 8.9% of CP, respectively (median time since last
dose of PCV7 13 months). In addition 6.7, 3.3 and 20%
of CHC had received one, two or three doses of PCV7
respectively (median time since last dose of PCV7: 26
months).
Lymphocyte subsets
Results for each LSS are summarized in Table 1. Overall,
these results confirmed significant age-specific differ-
ences in lymphocyte counts and proportions between
predominately HAART-treated children with paHIV,
healthy children and healthy young adults.
Baseline serology
Reverse cumulative distribution curves including base-
line serum pneumococcal polysaccharide-specific IgGpyright © Lippincott Williams & Wilkins. Unauthoconcentrations for AHC, CHC and CP are shown in
Fig. 2. Geometric mean concentrations (GMCs) of IgG
and proportion in each group above a cut-off of 0.35 and
1mg/ml at baseline are reported in Table 2. Comparing
CP with AHC, GMCs and proportions above 0.35 and
1mg/ml were significantly lower in CP than in AHC for
the four serotypes (7F, 9V, 18C and 23F). Both GMC and
proportion above 0.35mg/ml were significantly lower in
CP than in AHC for serotype 14, whereas GMC and
proportion above 0.35ml were significantly lower in CP
than in AHC for serotypes 19F and 6B, respectively.
Comparing CP with CHC, GMC and proportions above
0.35 and 1mg/ml were significantly lower in CP than in
CHC for two serotypes (6B and 23F). Both GMC and
proportion above 1mg/ml were significantly lower in
CP than in CHC for serotype 9V. Proportion aboverized reproduction of this article is prohibited.
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Fig. 2. (a–m) Reverse cumulative distribution curves showing the proportion (%) of individuals above increasing concentrations
of serotype-specific antibody for healthy children, young healthy adults and children with perinatally acquired HIV. Baseline
antibody concentration data are displayed in black. Post-immunization data for young healthy adults are shown in red and for HIV-
infected children in green. Vertical grey lines indicate cut-off of 0.35 and 1mg/ml. 0m, baseline; 1m/6m, 1month/6 months after
immunization; AHC, adult healthy control; CHC, child healthy control; CP, child patient; mcg, mg; S, serotype.
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Table 2. Geometric mean concentration of pneumococcal polysaccharide serotype-specific IgG, proportion with concentration above
0.35mg/ml and proportion with concentration above 1.0mg/ml for each group at baseline and for vaccinated groups at 1 and 6 months after
immunization.
ST Time-point
GMC (mg/ml) Proportion >0.35 mg/ml Proportion >1.0 mg/ml
CHC AHC CP CHC AHC CP CHC AHC CP
1 0m 0.29 0.51 0.35 0.4 0.62 0.48 0.1 0.27 0.15
1m – 5.43 3.32 – 1.00a 0.98a – 0.92a 0.81a
6m – 2.35 1.75 – 0.96a 0.94a – 0.65a 0.67a
3 0m 0.30 0.25 0.18 0.4 0.38 0.27 0.16b 0.03 0.02
1m – 1.00 0.60 – 0.85a 0.65a – 0.46a 0.29a
6m – 0.54 0.44 – 0.77a 0.58a – 0.19 0.21a
4 0m 0.33 0.33 0.29 0.47 0.58 0.42 0.2 0.15 0.15
1m – 3.29 2.53 – 1.00a 0.92a – 0.88a 0.75a
6m – 1.27 1.21 – 0.81a 0.83a – 0.58a 0.52a
5 0m 0.56 0.66 0.58 0.77 0.85 0.77 0.27 0.35 0.31
1m – 3.22 1.76 – 1.00 0.88 – 0.81a 0.73a
6m – 1.74 1.23 – 0.96 0.85 – 0.73a 0.56a
6A 0m 1.03 1.21 0.82 0.83 0.96 0.79 0.57 0.54 0.48
1m – 10.54c,d 3.56 – 1.00 0.98a – 1.00 a,e 0.81a
6m – 5.18c,d 2.20 – 1.00 0.92 – 0.96 a,e 0.71a
6B 0m 1.29f 1.08 0.68 0.97b 0.96e 0.73 0.63b 0.50 0.40
1m – 11.32c,d 3.31 – 1.00 0.94a – 1.00 a,e 0.83a
6m – 5.12c,d 2.04 – 1.00 0.88a – 0.96 a,e 0.75a
7F 0m 0.41g 0.91c 0.31 0.53 0.77e 0.46 0.27 0.50e 0.17
1m – 7.68c 3.01 – 1.00a 0.96a – 0.96a 0.92a
6m – 3.45 c 1.66 – 0.96 0.94a – 0.85a 0.65a
9V 0m 0.81f 0.67c 0.34 0.73 0.85e 0.58 0.4b 0.31e 0.08
1m – 4.58c 2.22 – 0.96 0.88a – 0.92 a,e 0.73a
6m – 1.93 1.18 – 0.96 0.85a – 0.77a 0.60a
14 0m 1.06 2.30c 0.73 0.77 0.85e 0.60 0.47 0.65 0.44
1m – 18.53 c 7.88 – 1.00 0.90a – 1.00 a,e 0.79a
6m – 11.36 5.44 – 1.00 0.90a – 1.00 a,e 0.81a
18C 0m 0.67 0.90c 0.35 0.73b 0.81e 0.50 0.37 0.50e 0.25
1m – 8.58c 2.51 – 0.96 0.85a – 0.96 a,e 0.75a
6m – 3.93c 1.31 – 0.92 0.81a – 0.85 a,e 0.60a
19A 0m 2.22 2.72 1.97 0.97 0.96 0.92 0.8 0.85 0.81
1m – 10.49c 7.14 – 1.00 0.98 – 1.00a 0.94a
6m – 5.80 4.46 – 1.00 0.98 – 0.92 0.92
19F 0m 1.10 1.43c 0.66 0.87 0.89 0.77 0.53 0.58 0.40
1m – 8.56 4.06 – 1.00 0.96a – 0.96a 0.88a
6m – 4.19 2.49 – 1.00 0.94a – 0.88a 0.75a
23F 0m 0.65f 0.62c 0.29 0.63b 0.69e 0.38 0.37b 0.35e 0.13
1m – 17.09c,d 2.12 – 1.00a 0.81a – 1.00 a,e 0.69a
6m – 7.25c,d 1.17 – 1.00a 0.75a – 0.92 a,e 0.56a
Chi-square and Fisher’s exact tests were used to compare baseline proportions above a cut-off between groups. One-way analysis of variance
(ANOVA) with Bonferroni correction was used to compare log-transformed antibody concentrations at baseline between groups. Chi-square was
used to compare proportions above a cut-off between groups at each time- point after immunization.McNemar’s test was used to detect changes in
proportion from baseline within groups. Repeated-measures ANOVA and analysis of covariance were used to compare log-transformed antibody
concentrations between and within group. Post-hoc analyses for simple effects were then performed as appropriate. 0m, baseline; 1m, 1 month
after immunization; 6m, 6 months after immunization; AHC, adult healthy control; CHC, child healthy control; CP, child patient; ST, serotype.
aProportion above cut-off significantly different before vs. after immunization (P<0.05).
bProportion above cut-off significantly different CHC vs. CP (P<0.05).
cGMC significantly different AHC vs. CP (P<0.05).
dGMC significantly different AHC vs. CP after adjusting for baseline (P<0.05).
eProportion above cut-off significantly different AHC vs. CP (P<0.05).
fGMC significantly different CHC vs. CP (P<0.05).
gGMC significantly different CHC vs. AHC (P<0.05).0.35mg/ml was significantly lower in CP than in CHC
for serotype 18C, whereas proportions above 1mg/ml
were significantly lower in CP than in CHC for two
serotypes (3B and 6B). Comparing CHC with AHC,
there was no significant difference in GMCs, proportions
above 0.35mg/ml and proportions above 1mg/ml apart
from for serotype 7F for which GMC was lower in CHC
than in AHC.pyright © Lippincott Williams & Wilkins. UnauthoSerology at 1 and 6 months
Geometric mean antibody concentrations and the
proportions above each cut-off at 1 and 6 months after
immunization are summarized in Table 2. GMCs for all
serotypes were significantly higher than baseline at both
time-points for both AHC and CP. GMCs were
significantly higher for AHC group than for CP at
1 month for eight of 13 serotypes (6A, 6B, 7F, 9V, 14,rized reproduction of this article is prohibited.
PCV13 in perinatally acquired HIV Bamford et al. 203918C, 19A, 23F) and remained significantly higher at
6 months for five of 13 serotypes (6A, 6B, 7F, 18C, 23F).
After adjusting for baseline antibody concentrations,
GMCs were significantly higher in AHC than in CP for
serotypes 6A, 6B and 23F at both 1 and 6-month time-
points.
Comparing proportions above 0.35mg/ml at baseline
with 1-month results, there was a statistically significant
increase for 11 of 13 serotypes for CP and five of 13
serotypes for AHC. For serotypes in which the increase in
proportion above 0.35mg/ml was non-significant, base-
line proportions were already high and increased to 1 or
just below. Increases in the proportions above 0.35mg/ml
persisted till 6 months for the majority of the serotypes.
There was a significant increase in proportions above
1mg/ml for all serotypes in both groups at the 1-month
time-point. The proportions above 1mg/ml were
significantly higher for AHC than for CP at 1 month
after immunization for six of 13 serotypes (6A, 6B, 9V, 14,
18C, 23F) and five of 13 at 6 months (6A, 6B, 14, 18C,
23F).
Factors predictive of 1-month antibody response
in children with perinatally acquired HIV
For results of analysis of factors predictive of 1-month
antibody response in children with paHIV, see Table,
Supplemental Digital Content 1 (http://links.lww.com/
QAD/A548). There was a highly significant association
between higher baseline antibody levels and higher 1-
month antibody levels for all 13 serotypes (P< 0.05).
After adjusting for baseline antibody concentration,
detectable viraemia was significantly associated with
lower 1-month antibody for 11 of 13 serotypes (P< 0.05)
and older age was significantly associated with lower 1-
month antibody response for six of 13 serotypes
(P< 0.05). After adjusting for age, baseline and viraemia,
higher percentage of life with undetectable viral load was
associated with higher 1-month antibody responses for
three of 13 serotypes (4, 19F, 23F) (P< 0.05). No
significant effect of prior PCV or PPV was found and
there was no association between any LSS and magnitude
of response.
Baseline opsonophagocytic assay comparison
between children with perinatally acquired HIV
and healthy children
In order to investigate naturally acquired immunity to
serotypes found in PCV13 and not PCV7, we assessed
OPA in CP and CHC groups at baseline. OPA was
performed on serum samples from all children aged above
8 years for serotypes 1, 5 and 7F. For serotype 1 and 5,
OPA titre was at least 8 in only four of 37 (11%) and one
of 37 (3%) CP, respectively, and two of 17 (12%) CHC for
both serotypes, despite a substantial proportion having
antibody concentrations above 0.35mg/ml. Conversely,
for serotype 7F, 26 of 37 (70%) CP and 16 of 17 (94%)
CHC had an OPA titre at least 8, respectively (P¼ 0.08).Copyright © Lippincott Williams & Wilkins. UnautIn view of these findings, further analysis of baseline OPA
data was only possible for serotype 7F (summarized in
Figure, Supplemental Digital Content 2, http://links.
lww.com/QAD/A548). OPA geometric mean titer
(GMT) was significantly higher in CHC [GMT¼ 1540,
1540, 95% confidence interval (CI) 621–3825)] than in
CP (GMT¼ 246, 95% CI 96–631, P¼ 0.02). This was
non-significant after adjusting for age, CD4þ percentage
and baseline serotype-specific IgG concentration.
Regression analysis found no correlation between
serotype-specific IgG concentration and OPA titre for
healthy children. After adjusting for age, there was a
significant positive correlation between log-transformed
serotype-specific IgG concentration andOPA titre for the
CP (regression coefficient¼ 1.17, 95% CI 0.44–1.90,
P¼ 0.003). After adjusting for age and serotype-specific
IgG concentration, viral load below 50 copies/ml was
strongly associated with a higher OPA titre (antilog
regression coefficient¼ 17.0, 95% CI 2.9–99.3,
P¼ 0.003).
One-month opsonophagocytic assay comparison
for children with perinatally acquired HIV and
healthy adults
Opsonophagocytic assay was performed for serotypes 1,
5, 7F and 19A (serotypes in PCV13 but not PCV7) for
both vaccinated groups, 1 month following vaccination.
A significantly higher proportion of AHC had an OPA
titre at least 8 for serotypes 1 and 5. For serotypes 7F and
19A, all AHC had an OPA titre at least 8, whereas, for CP,
45 of 47 had an OPA titre at least 8 (P¼ 0.54) (Fig. 3).
Comparing OPA GMT, 1 month following vaccination
between AHC and CP showed borderline significantly
higher OPA GMT for AHC for serotypes 1 (P< 0.05), 5
(P¼ 0.06) and 7F (P< 0.05). After adjusting for serotype-
specific IgG and CD4þ percentage, these differences were
non-significant. For both groups, regression analysis
revealed a significant positive correlation between
serotype-specific log-transformed IgG concentration
and OPA titre for all the four serotypes for CP and
three of four serotypes for AHC. Univariate analysis of
the CP results showed viral load below 50 copies/ml to be
strongly associated with higher OPA titre for all the four
serotypes assessed (P< 0.005). This effect remained
significant after adjusting for age and serotype-specific
IgG concentration for three of four serotypes (5, 7F, 19F)
(P< 0.05).Discussion
To our knowledge, this is the first study to present detailed
immunogenicity data for PCV13 in an HIV-infected
patient cohort. We measured serum IgG to all 13 vaccine
serotypes before and after immunization with a single
dose of PCV13. Serotype-specific IgG was present athorized reproduction of this article is prohibited.
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Fig. 3. Scatter graphs showing log-transformed opsonophagocytic assay titres against log-transformed serotype-specific IgG for
adult healthy controls and child patients 1 month after 13-valent pneumococcal conjugate vaccine. Grey vertical lines indicate
transformed value for the cut-offs of 0.35 and 1mg/ml. 1.39 on the Y-axis corresponds to an OPA titre of 4. IgG concentration
significantly correlated with OPA titre for all serotypes in both groups except 7F for AHC. Linear regression was used to test for
association between log-transformed OPA and IgG concentration. Chi-square and Fisher’s exact tests were used to compare
proportions. Serotype 1: CP (P<0.005, R2¼0.51); AHC (P<0.05, R2¼0.16). Serotype 5: CP (P<0.005, R2¼0.48); AHC
(P<0.005, R2¼ 0.70). Serotype 7F: CP (P<0.005, R2¼0.29); AHC (P¼0.4, R2¼0.01). Serotype 19A: CP (P<0.005, R2¼0.35);
AHC (P<0.05, R2¼0.18). A higher proportion of childrenwith paHIV hadOPA titres below 8 for serotypes 1 [AHC: 25/25 (100%)
vs. CP: 36/47 (77%), P¼0.007] and 5 [AHC: 25/25 (100%) vs. CP: 32/47 (68%), P¼0.001], despite the majority having serotype-
specific IgG concentrations greater than 0.35mg/ml. AHC, adult healthy control; CP, child patient; VL undetectable, viral load
below 50copies/ml; VL detectable, viral load above 50 copies/ml.baseline, although this did not consistently correspond
to detectable OPA activity. Children with paHIV
mounted relatively robust 1-month serotype-specific
IgG responses, which persisted to 6 months for the
majority of serotypes. Higher baseline IgG concentration
was associated with higher 1-month antibody levels, and
serum IgG correlated well with OPA following vaccina-
tion. Ongoing HIV viraemia was associated with an
impairment of both IgG and OPA responses.
The presence of serotype-specific IgG in unvaccinated
individuals is considered to be the result of natural
exposure through pneumococcal carriage [21,22]. We
found baseline IgG concentrations for healthy and HIV-
infected children to be broadly similar for the majority of
serotypes, consistent with existing reports [5–7,9,11],pyright © Lippincott Williams & Wilkins. Unauthosuggesting increased susceptibility to IPD in paHIVmight
not be attributable to lower levels of naturally acquired
circulating IgG. However, absence of detectable func-
tional antibody (as measured by OPA activity) in both
healthy and HIV-infected children despite measurable
naturally acquired IgG by ELISA suggests that IgG
measurement by ELISA in unvaccinated individuals may
not adequately predict protection. Nevertheless, baseline
IgG concentrations strongly predicted 1-month antibody
concentrations following vaccination. The mechanism by
which naturally acquired serological immunity develops
with age is not clear, especially for those invasive serotypes
that rarely colonize. It is possible that steady-state IgG
concentrations are a reflection of cumulative exposure to
pneumococcal antigens and other immune stimuli
resulting in persistent polysaccharide-specific IgGrized reproduction of this article is prohibited.
PCV13 in perinatally acquired HIV Bamford et al. 2041production by plasma cells. This might then be a proxy
measure for the integrity of the immune system at times
of past antigen exposure and also of the potential for
‘boostable’ memory response following immunization.
Geometric mean concentrations following immunization
were lower in HIV-infected children than healthy young
adults for a number of serotypes. After adjusting for
baseline antibody concentration, the response to three
serotypes (6A, 6B and 23F) remained relatively impaired.
These serotypes are particularly associated with IPD in
HIV-infected adults and children [23–25]. These
observations support the hypothesis that HIV infection
impacts upon acquired immunity in such away as to affect
the immune response to some pneumococcal serotypes
more than others. In healthy individuals, serotype-
specific IgG responses to PCV vary according to serotype,
despite uniform T-cell responses to vaccine carrier
protein [26]. It has been suggested that this may be a
result of variations in B-cell repertoire [26]. Reports from
our own group and others have demonstrated alterations
in B-cell phenotype in the context of HIV [27–36],
which can be related to both naturally acquired and
vaccine-induced pneumococcal immunity [27,32,34]. It
would be informative to investigate how detailed B and
T-cell phenotype might relate to our read-outs of
vaccine immunogenicity.
A cut-off of 0.35mg/ml is used as a correlate of protection
against IPD in infant PCV immunization [20]. Its utility as
a correlate for protection in other age and risk groups has
not been established. Our observation that many adults
and children have IgG concentrations above this cut-off
prior to immunization suggests that its usefulness in this
context is limited. Correlates of vaccine-induced
pneumococcal immunity outside of infancy and in risk
groups are needed and require large-scale efficacy studies,
which are much less feasible following the success of PCV
in reducing the burden of IPD. The results of the
Community Acquired Pneumonia IMmunization Trial
in Adults (CAPITA), a large-scale randomized trial
investigating efficacy of PCV13 in adults above 65 years of
age (http://clinicaltrials.gov/show/NCT00744263) may
provide some data to this effect, but will still not be
directly applicable to adolescent risk groups. The use of
protection against pneumococcal carriage as a surrogate
for protection against IPD is currently being explored and
will hopefully provide alternative measurable correlates of
protection [37].
Dosing schedule and timing of vaccination with PCV for
children with paHIV is currently debated [13,16–19].
Some argue that in the context of universal infant
immunization, PCV is not indicated due to efficient herd
immunity [17]. However, herd immunity is not as
effective in HIV-infected populations [38]. Our data on
the immunogenicity of a single dose of PCV13 in this
older age group can inform guidelines for its use in thisCopyright © Lippincott Williams & Wilkins. Unautcontext and also, perhaps more importantly, in settings
where herd immunity is a long way from being
established and where the numbers of older children
and adolescents with HIVare high and increasing. Lower-
valency PCVs have been introduced into national
schedules worldwide. Immunogenicity data in a range
of ages and risk groups and systematic monitoring for
serotype replacement will both be important when
considering the need for future introduction of higher-
valency vaccines.
We found immunogenicity to be limited in the context of
viraemia, consistent with the immunogenicity studies of
other vaccines in paHIV (reviewed in [39]) and
supporting recommendations to vaccinate once fully
suppressed on HAART and to consider revaccination/
boosting if primary vaccination occurred while being
viraemic [18]. When to start HAART in children beyond
infancy is also a subject to debate globally [40]. Recently
updated WHO guidelines recommend HAART for all
HIV-infected children under 5 years of age [41].
Although there are likely differences between our UK
cohort and HIV-infected children in resource-limited
settings (e.g. higher BMI, less OI), our data support the
argument that HAART should be initiated at the earliest
opportunity in order to optimize immune responses to
both natural infection and vaccine antigens. This is
especially relevant in resource-limited settings given the
relatively high exposure to infectious pathogens.
Our study has some limitations and we thus plan to study
in the future further time-points at 1 year or beyond, the
use of a booster dose to examine immune memory and
antigen-specific in-vitro B-cell studies. We were limited
ethically to recruiting healthy young adult controls rather
than age-matched controls, which may have helped
elucidate further differences between healthy and HIV-
infected children.
In conclusion, we have provided the first detailed
immunogenicity data for PCV13 in HIV-infected
children. This will both inform vaccination practices
and HAART treatment strategies in this unique and
vulnerable group.Acknowledgements
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